{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:08:21Z","timestamp":1779210501625,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Xizang Autonomous Region","award":["XZ2024ZR-ZY107(Z)"],"award-info":[{"award-number":["XZ2024ZR-ZY107(Z)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09691-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T03:49:10Z","timestamp":1775447350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose ticagrelor combined with aspirin in the prevention of early neurological deterioration of high-risk non-disabling ischemic cerebrovascular events: a PROBE clinical study"],"prefix":"10.1186","volume":"27","author":[{"given":"Mingli","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xidan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-5509","authenticated-orcid":false,"given":"Hua","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanlan","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"1","key":"9691_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1136\/jnnp-2014-308327","volume":"86","author":"P Seners","year":"2015","unstructured":"Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. J Neurol Neurosurg Psychiatry. 2015;86(1):87\u201394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"9691_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5853\/jos.2016.00073","volume":"18","author":"JE Siegler","year":"2016","unstructured":"Siegler JE, Samai A, Semmes E, Martin-Schild S. Early neurologic deterioration after stroke depends on vascular territory and stroke etiology. J Stroke. 2016;18(2):203\u201310.","journal-title":"J Stroke"},{"issue":"5","key":"9691_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000235987","volume":"28","author":"J Philipps","year":"2009","unstructured":"Philipps J, Thomalla G, Glahn J, Schwarze M, Rother J. Treatment of progressive stroke with tirofiban--experience in 35 patients. Cerebrovasc Dis. 2009;28(5):435\u20138.","journal-title":"Cerebrovasc Dis"},{"issue":"1","key":"9691_CR4","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.12.36","volume":"8","author":"P Liu","year":"2020","unstructured":"Liu P, Liu S, Feng N, Wang Y, Gao Y, Wu J. Association between neurological deterioration and outcomes in patients with stroke. Ann Transl Med. 2020;8(1):4.","journal-title":"Ann Transl Med"},{"issue":"2","key":"9691_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1985","volume":"11","author":"L Cong","year":"2021","unstructured":"Cong L, Ma W. Early neurological deterioration in cardiogenic cerebral embolism due to nonvalvular atrial fibrillation: predisposing factors and clinical implications. Brain Behav. 2021;11(2):e01985.","journal-title":"Brain Behav"},{"issue":"3","key":"9691_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ahj.2010.05.017","volume":"160","author":"Y Wang","year":"2010","unstructured":"Wang Y, Johnston SC. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010;160(3):380-6.e1.","journal-title":"Am Heart J"},{"issue":"2","key":"9691_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/ene.14541","volume":"28","author":"N Boulenoir","year":"2021","unstructured":"Boulenoir N, Turc G, Henon H, Laksiri N, Mounier-V\u00e9hier F, Girard Buttaz I, et al. Early neurological deterioration following thrombolysis for minor stroke with isolated internal carotid artery occlusion. Eur J Neurol. 2021;28(2):479\u201390.","journal-title":"Eur J Neurol"},{"issue":"2","key":"9691_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/STROKEAHA.116.015414","volume":"48","author":"P Seners","year":"2017","unstructured":"Seners P, Hurford R, Tisserand M, Turc G, Legrand L, Naggara O, et al. Is unexplained early neurological deterioration after intravenous thrombolysis associated with thrombus extension? Stroke. 2017;48(2):348\u201352.","journal-title":"Stroke"},{"issue":"2","key":"9691_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1210","volume":"9","author":"X Hou","year":"2019","unstructured":"Hou X, Chen W, Xu H, Zhu Z, Xu Y, Chen H. The rate of early neurological deterioration occurring after thrombolytic therapy: a meta-analysis. Brain Behav. 2019;9(2):e01210.","journal-title":"Brain Behav"},{"issue":"10","key":"9691_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/neurintsurg-2016-012633","volume":"9","author":"DC Haussen","year":"2017","unstructured":"Haussen DC, Bouslama M, Grossberg JA, Anderson A, Belagage S, Frankel M, et al. Too good to intervene? Thrombectomy for large vessel occlusion strokes with minimal symptoms: an intention-to-treat analysis. Journal of neurointerventional surgery. 2017;9(10):917\u201321.","journal-title":"Journal of neurointerventional surgery"},{"issue":"28","key":"9691_CR11","doi-asserted-by":"publisher","first-page":"19900","DOI":"10.18632\/oncotarget.24945","volume":"9","author":"X Yi","year":"2018","unstructured":"Yi X, Lin J, Wang Y, Zhou J, Zhou Q, Wang C. Response to clopidogrel is associated with early neurological deterioration after acute ischemic stroke. Oncotarget. 2018;9(28):19900\u201310.","journal-title":"Oncotarget"},{"issue":"4","key":"9691_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/STROKEAHA.118.023789","volume":"50","author":"A Berberich","year":"2019","unstructured":"Berberich A, Schneider C, Reiff T, Gumbinger C, Ringleb PA. Dual antiplatelet therapy improves functional outcome in patients with progressive lacunar strokes. Stroke. 2019;50(4):1007\u20139.","journal-title":"Stroke"},{"issue":"1","key":"9691_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(1):70\u20138.","journal-title":"JAMA"},{"issue":"1","key":"9691_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. Jama-journal of the american medical association. 2016;316(1):70\u20138.","journal-title":"Jama-journal of the american medical association"},{"issue":"1","key":"9691_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0788-8","volume":"17","author":"X Yi","year":"2017","unstructured":"Yi X, Wang C, Zhou Q, Lin J. Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. BMC Neurol. 2017;17(1):4.","journal-title":"BMC Neurol"},{"issue":"25","key":"9691_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120(25):2577\u201385.","journal-title":"Circulation"},{"issue":"27","key":"9691_CR17","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","volume":"385","author":"Y Wang","year":"2021","unstructured":"Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520\u201330.","journal-title":"N Engl J Med"},{"issue":"9749","key":"9691_CR18","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet (London, England). 2010;376(9749):1320\u20138.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"9691_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038\u201347.","journal-title":"Eur Heart J"},{"issue":"4","key":"9691_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/dmd.110.037143","volume":"39","author":"D Zhou","year":"2011","unstructured":"Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 2011;39(4):703\u201310.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"9691_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2165\/11595930-000000000-00000","volume":"32","author":"H Li","year":"2012","unstructured":"Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig. 2012;32(2):87\u201397.","journal-title":"Clin Drug Investig"},{"issue":"15","key":"9691_CR22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","volume":"73","author":"N Ferri","year":"2013","unstructured":"Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681\u2013709.","journal-title":"Drugs"},{"issue":"11","key":"9691_CR23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"10204","key":"9691_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","volume":"394","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet (London, England). 2019;394(10204):1169\u201380.","journal-title":"Lancet (London, England)"},{"key":"9691_CR25","doi-asserted-by":"crossref","unstructured":"James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ (Clinical research ed). 2011;342(null):d3527.","DOI":"10.1136\/bmj.d3527"},{"issue":"17","key":"9691_CR26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1093\/eurheartj\/ehz821","volume":"41","author":"RHM Furtado","year":"2020","unstructured":"Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, et al. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. Eur Heart J. 2020;41(17):1625\u201332.","journal-title":"Eur Heart J"},{"issue":"2","key":"9691_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10557-020-06940-y","volume":"34","author":"S Ma","year":"2020","unstructured":"Ma S, Li Z, Yu P, Song H, Jiang Z, Li Y, et al. Efficacy and safety of potent oral P2Y12 inhibitors in medically managed ACS patients: a meta-analysis. Cardiovasc Drugs Ther. 2020;34(2):199\u2013208.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"14","key":"9691_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367.","journal-title":"Eur Heart J"},{"issue":"1","key":"9691_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016;375(1):35\u201343.","journal-title":"N Engl J Med"},{"key":"9691_CR30","volume":"365","author":"Y Wang","year":"2019","unstructured":"Wang Y, Chen W, Lin Y, Meng X, Chen G, Wang Z, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. BMJ (Clinical research ed). 2019;365:l2211.","journal-title":"BMJ (Clinical research ed)"},{"issue":"3","key":"9691_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"9691_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791\u2013800.","journal-title":"N Engl J Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09691-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09691-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:30:27Z","timestamp":1779208227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09691-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9691"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09691-7","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiment follows the Ethical Review Measures for Biomedical Research Involving Human Subjects (2016), the Declaration of Helsinki (2013), the CIOMS Guidelines (2002), and the GCP. Under the guidance of GCP, the study is carried out according to the requirements of the protocol approved by the ethical committee of the First Affiliated Hospital of Dalian Medical University (Number Project ID PJ-KS-KY-2023-03(X)), to ensure the scientific nature of the research and protect the health and rights of the participants. The results of this study will be published as a journal article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. The participant information materials and informed consent forms are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}